Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Good morning, slightly off topic but am hosting a webinar for companies that listed in UK in 2021. One of the three companies presenting is insig AI who provide AI analytics solutions to asset managers. To find out more about the event and register please go to
https://www.fmp-tv.co.uk/2021/11/18/2021-ipo-webinar-2nd-december-pyx-resources-artisanal-spirits-co-insig-ai/
Interesting, thanks. I have an avge of 108p on KCT. I already hold S4 Capital (Sorrell's co).
I bought 5,000 at 78p in Sept 2017 when they were St Ives press. They have done well to transform the business to digital
and could well be ta target for Sir Martin Sorrell or perhaps Eagle Eye Solutions, a fast growing company in data processing
and an electronic loyalty programme for major supermarkets and now gathering some premium accounts in N America.
Has no one posted on KCT since September? Why the big fall today? Is it a technical thing? I am a recent and happy buyer.
This new team have a really good history of getting things done. Can only be a positive for the future of this one.
https://www.decisionmarketing.co.uk/news/kin-carta-brings-in-new-senior-team-in-fresh-shake-up
RNS today of full year results showing a year of transition as expected.
Stripping out the various negative impacts of the transition shows a company consolidating and growing revenues and profits.
It's a fragmented global operation stitched together with a new strategy to provide clients with a wider portfolio of services. If each segment continues to attract new clients and cross-refer work, they could do very well and it the valuation looks attractive The only outlier appears to be Hive, both in terms of its market and recent performance. Maybe the share price would respond positively if they decided to ditch it.
If they execute well, we could see a steady rise from here.
Now the company has disposed of its legacy print business and re-positioned as a new tech marketing business, will the results due on 9th October, begin to show better margins. Likely to have a bunch of costs due to restructuring, which may hit net margin, so let's see if they still look good enough to boost the share price.
Might even become a target for Sir Martin Sorrell's S4 Capital after they swallowed Mediamonks.
Good luck all long-term holders.